Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer’s Drugs and Medicare: A Case For Pre-Approval Discussions

Executive Summary

Medicare's Part D plan bidding schedule and uncertainty over the Alzheimer’s drug pipeline is putting plan sponsors in a difficult situation as they contemplate their 2018 bids.

Advertisement

Related Content

US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Preapproval Safe Harbor Should Extend 18 Months, Payers And Sponsors Say
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification
Rx Economic Information-Sharing Concept Getting Renewed Push
Axovant Builds A Case For GSK’s 5-HT6 Castoff In Alzheimer’s

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel